ZAI LAB LTD0000006 - Asset Resilience Ratio

Latest as of March 2026: 0.91%

ZAI LAB LTD0000006 (1ZLB) has an Asset Resilience Ratio of 0.91% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

€10.00 Million
≈ $11.69 Million USD Cash + Short-term Investments

Total Assets

€1.10 Billion
≈ $1.28 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2025)

This chart shows how ZAI LAB LTD0000006's Asset Resilience Ratio has changed over time. Check strategic asset allocation of ZAI LAB LTD0000006 to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down ZAI LAB LTD0000006's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ZAI LAB LTD0000006 (1ZLB) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €10.00 Million 0.91%
Total Liquid Assets €10.00 Million 0.91%

Asset Resilience Insights

  • Limited Liquidity: ZAI LAB LTD0000006 maintains only 0.91% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

ZAI LAB LTD0000006 Industry Peers by Asset Resilience Ratio

Compare ZAI LAB LTD0000006's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Verona Pharma plc
F:I9SA
Biotechnology 0.00%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Syndax Pharmaceuticals Inc
NASDAQ:SNDX
Biotechnology 46.79%
Neuren Pharmaceuticals Ltd
AU:NEU
Biotechnology 90.43%
Vor Biopharma Inc
NASDAQ:VOR
Biotechnology 63.47%
Chengdu Kanghua Biological Products
SHE:300841
Biotechnology 1.19%
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488
Biotechnology 4.35%

Annual Asset Resilience Ratio for ZAI LAB LTD0000006 (2021–2025)

The table below shows the annual Asset Resilience Ratio data for ZAI LAB LTD0000006.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.85% €10.00 Million
≈ $11.69 Million
€1.17 Billion
≈ $1.37 Billion
-26.98pp
2024-12-31 27.83% €330.00 Million
≈ $385.80 Million
€1.19 Billion
≈ $1.39 Billion
+26.26pp
2023-12-31 1.57% €16.30 Million
≈ $19.06 Million
€1.04 Billion
≈ $1.21 Billion
--
2022-12-31 0.00% €0.00
≈ $0.00
€1.22 Billion
≈ $1.43 Billion
--
2021-12-31 27.64% €445.00 Million
≈ $520.25 Million
€1.61 Billion
≈ $1.88 Billion
--
pp = percentage points

About ZAI LAB LTD0000006

F:1ZLB Germany Biotechnology
Market Cap
$2.06 Billion
€1.76 Billion EUR
Market Cap Rank
#6418 Global
#963 in Germany
Share Price
€1.57
Change (1 day)
+0.00%
52-Week Range
€1.36 - €3.30
All Time High
€152.00
About

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for … Read more